Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026)

Lexeo Therapeutics has disclosed Income from Continuing Operations across 5 years of filings, most recently posting 20196000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 20196000.0, up 38.16% year-over-year; the trailing twelve-month figure through Mar 2026 was 87505000.0 (up 19.95% YoY), and the FY2025 annual result was 103222000.0, down 4.97% from the prior year.
• Income from Continuing Operations came in at 20196000.0 for Q1 2026 at Lexeo Therapeutics, up from 20923000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 13441000.0 in Q2 2023 to a low of 32656000.0 in Q1 2025.
• The 5-year median for Income from Continuing Operations is 20283000.0 (2025), against an average of 21101266.67.
• Across the five-year window, Income from Continuing Operations sank 82.73% in 2024 and jumped 38.16% in 2026, its largest moves.
• Lexeo Therapeutics' Income from Continuing Operations stood at 14577000.0 in 2022, then grew by 2.68% to 14187000.0 in 2023, then sank by 82.73% to 25924000.0 in 2024, then increased by 19.29% to 20923000.0 in 2025, then grew by 3.47% to 20196000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 20196000.0 (Q1 2026), 20923000.0 (Q4 2025), and 20283000.0 (Q3 2025), per Business Quant data.